Image For Activity Cover
P2Y12 Inhibition in Patients Requiring Oral Anticoagulation after Percutaneous Coronary Intervention: The SWAP-AC–2 Study (JACC Cardiovascular Interventions June 2024)

Among patients treated with a novel oral anticoagulant (NOAC) undergoing percutaneous coronary intervention (PCI), combination therapy with clopidogrel (i.e., known as dual antithrombotic therapy [DAT]) is the treatment of choice. However, there are concerns for individuals with impaired response to clopidogrel.


JACC: Cardiovascular Interventions Editor-in-Chief
David J. Moliterno, MD, FACC

JACC: Cardiovascular Interventions CME/MOC Editor
Michael C. McDaniel, MD

Luis Ortega-Paz, MD, PhD
Dominick J Angiolillo, MD, PhD

Important Dates

Date of Release: June 10, 2024
Term of Approval/Date of CME/MOC Expiration: June 9, 2025

Availability: On-Demand
Expires on Jun 09, 2025
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
Android App Download IOS App Download Powered By